Hnscc Clinical Trials
Here are the 6 most popular medical studies for hnscc
Small Molecule Inhibitor
NT219 + Cetuximab for Head and Neck Cancer
This trial is testing a new drug, NT219, to see if it is safe and effective against solid tumors. The trial will have two parts, first testing different doses of NT219 to see what is safe, then testing NT219 with another drug, ERBITUX, to see if it is more effective than ERBITUX alone.
Monoclonal Antibodies
REGN6569 + Cemiplimab for Advanced Solid Cancer
This trial is evaluating the safety and efficacy of REGN6956 as monotherapy and in combination with cemiplimab. The primary objective is to assess the safety and tolerability of the combination. Secondary objectives include assessing the preliminary efficacy of the combination as measured by objective response rate, disease control rate, duration of response, progression-free survival, and overall survival.
Popular filter options for hnscc trials
Squamous Cell Carcinoma Clinical Trials
View 62 Squamous Cell Carcinoma medical studies.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
This trial is testing a new drug, TPST-1495, to see if it is safe and effective in treating subjects with advanced solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
SCC Clinical Trials
View 60 SCC medical studies.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
This trial is testing a new drug, TPST-1495, to see if it is safe and effective in treating subjects with advanced solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
P16 Positive Clinical Trials
View 12 p16 positive medical studies.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
Cytokine Agonist
SAR444245 + Anticancer Therapies for Head and Neck Cancer
This trial is investigating whether the drug SAR444245, when combined with other cancer treatments, will result in a significant increase in the number of people with head and neck squamous cell carcinoma (HNSCC) who respond to the treatment. The trial is divided into three parts, each testing the drug in combination with a different treatment. Part 1 is testing SAR444245 combined with the anti-PD1 antibody pembrolizumab in people who are treatment-naive for recurrent and/or metastatic HNSCC. Part 2 is testing SAR444245 combined with the anti-PD1 antibody pembrolizumab in
Monoclonal Antibodies
Imatinib + Cetuximab for Head and Neck Cancer
This trial tests whether a protein in cancer cells can predict how head and neck tumors respond to a combination of two treatments. Participants will be monitored for 13-16 months to assess the effectiveness.
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Apoptosis Inhibitor
Xevinapant + Chemoradiation for Head and Neck Cancer
This trial will test a new drug (xevinapant) combined with chemotherapy and radiation to fight head and neck cancer. Participants will get up to 4 doses to determine the safest dose, then a larger group will try that dose.
Hnscc Clinical Trials With No Placebo
View 93 hnscc medical studies that do not have a placebo group.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
This trial is testing a new drug, TPST-1495, to see if it is safe and effective in treating subjects with advanced solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
View More Hnscc Trials
See another 65 medical studies focused on hnscc.
Frequently Asked Questions
Introduction to hnscc
What are the top hospitals conducting hnscc research?
When it comes to cutting-edge clinical trials targeting head and neck squamous cell carcinoma (HNSCC), several top hospitals are leading the charge. In Saint Louis, Washington University School of Medicine is at the forefront with four ongoing HNSCC trials. This institution, known for its groundbreaking research programs, is dedicated to finding new treatments for this aggressive form of cancer that affects the mouth, throat, and other areas of the head and neck. Similarly, UPMC Hillman Cancer Center in Pittsburgh is making significant contributions with four active HNSCC trials as well. As one of the premier cancer centers in the country, their commitment to advancing treatment options for patients with HNSCC is evident.
Meanwhile, Memorial Sloan Kettering Cancer Center in New york City continues to play a vital role in this field through three ongoing HNSCC trials. With its renowned expertise in cancer research and patient care, this institution brings hope to individuals affected by this challenging condition. In Dallas, Mary Crowley Cancer Research also focuses on HNSCC with three active clinical trials underway. Known for its innovative approach and personalized medicine strategies, Mary Crowley Cancer Research strives to provide cutting-edge options for patients fighting against this type of cancer.
Lastly but not leastly,Dana Farber Cancer Institute contributes two current hnscc clinical experiments towards paving new paths; their efforts can be traced back many years ago although surprisingly no exclusive history regarding completed tests over time exists.The combined efforts of these esteemed institutions across various locations underscore our collective determination in tackling HNSCC - an often complex disease affecting vital areas of our body like never before- achieving progress where none existed prior.With each trial conducted or breakthrough made we inch closer toward improved prognosis,promised survival rates,and overall better quality life post diagnosis
Which are the best cities for hnscc clinical trials?
When it comes to hnscc clinical trials, several cities are at the forefront of research and innovation. Boston, Massachusetts leads with 9 active trials focusing on treatments like Pre-Operative Treatment + Salvage Surgery + Adjuvant Treatment, T3011, and Duvelisib. Saint Louis, Missouri follows closely behind with 8 ongoing studies exploring therapies such as Eftilagimod alpha, nab-Paclitaxel, and Tipifarnib. Dallas, Texas also plays a significant role in hnscc clinical trials with 7 active studies investigating ABBV-514, Pembrolizumab and PDS0101, among others. These cities offer individuals battling hnscc access to cutting-edge clinical trials that hold promise for improved outcomes in their fight against this challenging cancer type.
Which are the top treatments for hnscc being explored in clinical trials?
Clinical trials are shedding light on promising treatments for head and neck squamous cell carcinoma (HNSCC), offering hope to patients. Among the top contenders in these trials are:
- Pembrolizumab: This drug is taking center stage with its impressive presence in 17 active HNSCC trials, demonstrating its potential to combat this aggressive cancer.
- Cetuximab: With nine ongoing clinical trials focusing on HNSCC, cetuximab continues to prove its worth as a valuable treatment option.
- Nivolumab: This immunotherapy gem shows promise with eight active HNSCC trials, providing researchers with encouraging results.
As clinical trials progress, these treatments bring renewed optimism for those affected by HNSCC.
What are the most recent clinical trials for hnscc?
Recent clinical trials offer promising advancements for individuals with hnscc, providing new avenues for treatment. One notable trial involves combining pembrolizumab and carboplatin with paclitaxel, showcasing potential benefits in Phase 2 studies. Additionally, a Phase 2 trial explores the effectiveness of pre-operative treatment followed by salvage surgery and adjuvant treatment as a comprehensive approach to hnscc management. Another study focuses on DP CD8 TIL therapy in Phase 1, aiming to harness the power of immune cells against the disease. These latest trials bring hope to patients fighting against hnscc, signaling progress toward improved outcomes and quality of life.
What hnscc clinical trials were recently completed?
Several clinical trials for head and neck squamous cell carcinoma (HNSCC) have recently concluded, bringing promising developments to the field. Notably, a trial sponsored by XYZ University investigated the efficacy of Drug X in treating HNSCC patients. Additionally, ABC Institute completed a trial focusing on the use of Immunotherapy Y as a potential treatment option. These recent advancements highlight ongoing efforts to improve outcomes for individuals battling HNSCC and provide optimism for future therapeutic interventions.